Mycosis Fungoides
Conditions
Brief summary
This phase II trial studies how well low dose total skin electron beam radiation therapy and mechlorethamine hydrochloride gel work in treating patients with mycosis fungoides. Total skin electron beam radiation therapy uses high energy x-rays directed at the entire surface of the body to kill cancer cells and shrink tumors. Mechlorethamine hydrochloride gel may help patients in remission of disease, reduction in disease staging, and enhanced quality of life. Giving total skin electron beam radiation therapy and mechlorethamine hydrochloride gel may work better in treating patients with mycosis fungoides.
Detailed description
PRIMARY OBJECTIVES: I. To assess the time to progression of patients treated with total skin electron beam therapy (TSEBT) followed by the year-long maintenance mechlorethamine hydrochloride gel (Valchlor) regimen. SECONDARY OBJECTIVES: I. To assess the response rate (complete response \[CR\] and partial response \[PR\]) of patients treated with total skin electron beam therapy (TSEBT) followed by the year-long maintenance Valchlor regimen.
Interventions
DRUGMechlorethamine Hydrochloride Gel
Given topically
PROCEDURETotal Skin Electron Beam Radiation Therapy
Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
Sponsors
Actelion
Sidney Kimmel Cancer Center at Thomas Jefferson University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Documentation of diagnosis as evidenced by one or more clinical features consistent with mycosis fungoides cutaneous T-cell lymphoma * Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with requirements of the study * Skin biopsy specimen of representative lesion obtained at screening of study and deemed diagnostic of mycosis fungoides by principal investigator * Mycosis fungoides patients that have stage T2-4 N0-1 M0B0 disease * Availability of subject to be observed for up to 18 months post-screening evaluation * Life expectancy greater than 6 months
Exclusion criteria
* Pregnant or breast-feeding females * Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data * Patients diagnosed with Sezary syndrome; Sezary syndrome is equivalent to mycosis fungoides that develops to stage IVA/B with B2 (high blood tumor burden) involvement, and as such requires a more aggressive treatment regimen than Valchlor or TSEBT * Underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to undergo treatment * Minimum 3 weeks since prior systematic treatment or phototherapy * Exclusion of people that do not understand the risks, such as decisionally-impaired individuals, prisoners, and vulnerable populations
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to progression | Up to week 54 | Will be evaluated using the Kaplan-Meier estimator of the survival curves. |
Countries
United States
Outcome results
None listed